PM-1 (PM-Scl) Antibody
Autoantibodies are antibodies that specifically recognize self-antigens (proteins) and are involved in the pathogenesis of autoimmune diseases. Detection of autoantibodies is very crucial in the diagnosis and monitoring of such autoimmune diseases. PM-1 autoantibody is often detected in patients with homogeneous overlap connective tissue disease characterized by Raynaud’s phenomenon, myositis, scleroderma and arthritis. PM-1 antibodies are directed against PM/Scl complex, which is also referred to as human exosome. It is a complex of proteins found mostly in the nucleolus and is involved in ribosomal RNA processing and messenger RNA degradation. Antibodies to PM/Scl complex are present in approximately 30% of PM/Scl overlap syndrome, 8% of polymyositis, 11% of dermatomyositis, and 2% of scleroderma. Presence of these antibodies is considered to be a good prognostic factor as they are not associated with malignancy. Laboratory investigation of PM-1 antibody along with other antibody markers is commonly used in the differential diagnosis of systemic sclerosis.
- It serves as a specific marker of PM/Scl overlap syndrome
- Useful in the differential diagnosis of PM/Scl overlap syndrome from other idiopathic myositis and scleroderma
- Has prognostic value since cardiac and renal involvement are rare in PM-1 positive patients
Increased in:
- Polymyositis
- Scleroderma
- PM/Scl overlap syndrome
- Dermatomyositis
- Systemic sclerosis
- Systemic lupus erythematosus
Negative (< 20 EU/mL)
Enzyme Immunoassay, enzyme-linked immunosorbent assay (ELISA), Indirect immunofluorescence, Immunodiffusion, Immunoprecipitation
Serum (SST tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Arthritis Rheum. 2004;50:565-569. [PMID: 14872500]
- Autoimmun Rev. 2007;6:432-437. [PMID: 17643929]
- Autoimmun Rev. 2009;8:373-378. [PMID: 19103309]
- Ann Rheum Dis. 2011;70:476-481. [PMID: 21081523]